Tracer studies in GSK for Discovery and Development
|
|
- Damon Hampton
- 5 years ago
- Views:
Transcription
1 Tracer studies in GSK for Discovery and Development 3 rd June a ripple or a wavefront? Graeme Young, DMPK, GlaxoSmithKline R&D, Ware, UK
2 Outline Historical use of AMS at GSK variety of ADME studies; no microdose/microtracer adoption Emerging clinical study designs microdoses (PK & DDI assessments) What has changed in recent months? Microdosing more predictive than we thought? µtracer dosing as predictive as we expect! State of play of microdose and 14 C-tracer studies at GSK
3 Historical use of AMS at GSK
4 Historical use of AMS at GSK All (pre-2006) GSK AMS studies supported by Xceleron Ltd. Some initial sample prep. carried out by GSK including fractionation by HPLC for metabolite profiling Dedicated laboratories for AMS work used throughout temporary laboratory used for pilot and early studies part of conventional ADME lab converted into AMS prep lab AMS sample prep. suite now established at GSK AMS used for atypical projects : more recently..starting to see use for more mainstream assessments
5 History of AMS use at GSK a variety of ADME studies 1998 ; 1999 ; 2001 ; 2003 ; Pilot low dose rat excretion balance study (Garner et al., JPBA, 2000, 24, p ) Pilot low radioactive dose Clinical excretion balance study (Young G et al., Xenobiotica, 2001, 31 (8/9), p619-32) Serum metabolite profiling for Clinical study & In vitro blood cell association study Dog low dose excretion balance study 2003/4 ; Dog plasma and rat tissue metabolite profiling studies 2004/5 ; Low radioactive dose Clinical study [aka Nanotracer or light label ] 2005/6 ; 2 Conventional dose Clinical studies In-house capability: 2006 ; Low dose animal studies (potent respiratory molecules) 2007; Conventional dose Clinical study 3 dose arms incl. repeat cold dose then 14 C dose 2008/9; Low dose animal studies 2009; Clinical IV tracer study PK plus metabolite profiling (MS, NMR & AMS) The pre-2006 studies have been outlined in: Young G.C. & Ellis.W.J., AMS in drug development at GSK, Nucl. Inst. and Methods in Phys. Res. B, 2007, 259:752.
6 Emerging Clinical study designs
7 Emerging Clinical study designs µdose designs ( 1/100 th of clinically active dose and 100µg) to investigate early PK (IV route) to investigate DDI liability (PO route) - NCE administered as µdose; Cyp450 inhibitor at therapeutic dose!! analytical method may not be AMS; LCMS may suffice Early 14 C study by therapeutic route and at therapeutic dose (aka; an early HRS) to investigate systemic exposure to RDM - assist in design of QT liability study IV 14 C µtracer + concomitant Oral therapeutic doses more on this later..
8 So what has changed..?
9 1. CREAM Trial : Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs, Clin. Pharmacol. Ther., 2006, 80(3), EUMAPP Trial : 3. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? ; Beaumont K and Smith D (Pfizer), Current opinion in Drug Discovery & Dev., 2009, 12(1):61-71 What has changed in recent months/years Regulations MIST (Feb 2008) emphasis on understanding human metabolism Data from CREAM 1, EUMAPP 2 + other published data 3 >80% predictability for microdose to therapeutic dose (Oral and IV) 100% (?) predictive for IV route Availability of clinics that conduct IV admin. of 14 C (to Regulatory req.) conventional studies (<1µCi) UK, Europe and US (Aug 09); no dosimetry emergent µtracer study design and adoption by several Pharma in GSK; progression decision made based on this data increased benefit of 14 C presence on the cold metabolism approach repeat dose 14 C study designs are now feasible
10 State of play of microdose and tracer studies in GSK
11 Clinical study type, primary output, decisions and customer(s) Completed Jan 2010 Study Type DDI study Impact Primary - validated output Phase 0 screen Decisions for Main Customer(s) interaction liability of pre-candidates Planned start: July 2010 PK, Metabolite profiling & ID Completed April 2010 Microdose Pharmacokinetics Candidate selection/ 1 0 Endpoint - Absolute F% (Phase 0 approach) progression/termination 2 0 Endpoint (stand - metabolism alone) (incl. bile) Enhanced [Cold Phase or 14 I C design study]; (Human Regional Gut Absorption study) dose of 100µg via IV and/or PO route IV 14 C tracer + Oral therapeutic (concomitantly) Program team 1 0 Endpoint - PK Impact - CS decision/planning for Oral FTIH study [Rapid compared to previous experience in GSK] Planned start:september 2010 Early stages of discussion/planning 1 Absolute 0 Endpoint - Absolute F% F% Direct formulation Project Team Enhanced Phase I design (Human RGA study) Metabolism info. effort? Clinical PK/DMPK Completed July Endpoint Formulation - Absolute scientists F% Project progression? 2 0 Endpoint Regulators - Metabolite profiling and ID Planned 14 start: June 2010 C Nanotracer Dosing June 2010 ADME info. Assessment of Impact acceptable F% ; PK, Metabolite profiling & ID Low dose potent compound DMPK (aka light label ) (incl. mass balance & metabolic liabilities compound progressed 1 0 Endpoint - IV PK to predict for low 14 C human ADME Safety Assessment change extractability) & conventional in therapeutic Human route Endpoints - Mass balance, 14 C Regulators 2ADME 0 Endpoint study - Extractability (HRS); and exposure, metabolite Aid design profiling QTc study metabolism (including bile) and ID Dosed via therapeutic route
12 Example 1..
13 Clinical microdose DDI study Aim - to confirm effect of CYP3A4 inhibition on PK of GSK Drug-Y at a microdose clinical evidence at therapeutic dose of GSK Drug-Y [DDI with Kaletra] use approach for decision on back-up compounds Period 1: 12 human volunteers administered 50µg GSK Drug-Y (250nCi) PO Period 2: Repeat doses of bid (Q12) for 5 days on day 3, administered 50µg GSK Drug-Y (250nCi) PO
14 Clinical microdose DDI study Comparison of therapeutic dose and microdose admin. of Drug-Y with/without co-admin of CYP450 inhibitor Concentration in plasma [ng or pg/ml] same magnitude of DDI for both micro and therapeutic dose of Drug-Y Drug Y (50mg) [ng/ml] Drug Y (50mg) + Kaletra [ng/ml] Drug Y (50µg) [pg/ml] Drug Y (50µg) + ketconazole [pg/ml] Time (Hours) Notes: 1. Sensitive LC/MS method would have provided the answer. 2. Exposure did not scale very well when normalised for dose but DDI risk highlighted.
15 Example 2..
16 Clinical microdose Phase 0 IV PK study Aim - to establish the clinical IV PK of GSK Drug-Z (novel target) with clear GO/No Go decision on IV Clearance; use the IV clearance data to model for Oral dosing in FTIH dose escalation study very different clearance in rat and dog need to define which equates with human PK 6 human volunteers administered 100µg GSK Drug-Z (250nCi) IV infusion Blood for plasma at multiple timepoints to 48 hours Parent drug PK; Go/No Go: Clearance >1/3 LBF (Cl >30L/h) Total drug-related material PK Urine collection for 0-24 hours Definition of renal excretion of total drug-related material
17 Clinical microdose Phase 0 IV PK study Individual profiles for total radioactivity and GSK Drug-Z in plasma to 24 hours after IV infusion (pg equiv. & pg/ml) LLOQ ~900fg/mL Notes: 1. Parent drug accounts for ~50% of total radioactivity in systemic 2. Similar data for all 6 volunteers (CV of 20% for parent PK)
18 Clinical microdose Phase 0 IV PK study Plasma clearance of ~20L/h GO/No Go decision for progression! IV data used to model likely oral exposures Use to plan for starting dose and dose escalation in FTIH Additionally. % drug in urine estimated as 20% Metabolite profiling not conducted due to non-therapeutic route and inability to conduct structural ID of metabolites
19 Example 3..
20 IV Tracer + Therapeutic Oral The Purpose Aim - to understand reason(s) for variable systemic exposure in humans following oral dosing poor/variable absorption? first pass metabolism? terminate project or re-direct effort eg. drug formulation Attraction of the approach rapid evaluation study (relatively low effort) possibility of piggy-backing to another Phase 1 study.enhanced study - Age versus gender - Formulation assessment - Food effect
21 IV Tracer + Therapeutic Oral Dose The Design Study design IV 14 C-tracer dose administered concomittantly at T max of Oral therapeutic dose in a single dosing period Design established in 1970 s; 13 C-drug by IV route, non-labelled by oral route, both at therapeutic levels IV 14 C-dose at 1/500 th of oral <270nCi 14 C
22 IV Tracer + Therapeutic Oral Dose Conventional IV clinical dose approach: Dosing GMP Manufacture IV tolerance Intravenous tox. Animal dosimetry
23 IV Tracer + Therapeutic Oral Dose Microdose general guidance applies but as tracer administered with oral dose (safety package in place). X Intravenous tox. X IV tolerance Adapted GMP Manufacture* Dosing X Animal dosimetry *Traditional GMP manufacture still required for oral dose
24 IV µtracer + Therapeutic Oral dose Example study design: IV tracer ( µg + oral therap. dose ( mg; 8 humans IV dose given at T max of oral dose (2.75-3h), as 15 minute infusion Blood collections for plasma, to 72 hours; urine collection, 0-24 hours IV followed by AMS (total RDM, parent PK [UPLC], metabolism) PO dose followed by LC/MS/MS (parent PK) Concomitant use of IV & oral negates most worries over linearity better design than separate microdose absolute F% study better design than conventional cross-over absolute F% study(?)
25 Data from MS analysis of plasma Plasma concentrations of Drug X (ng/ml) Individual plasma concentrations (ng/ml) of Drug X following a single oral dose of 250mg Drug X to 8 healthy volunteers CV for Drug X AUC of ~90% [reflects data seen in FTIH] Time (hours)
26 Data from UPLC-AMS (Parent drug isolation and analysis) Individual plasma concentrations (ng/ml) of Drug X following a single IV infusion of 100µg [ 14 C]-Drug X Plasma concentrations (ng/ml) CV for Drug X; AUC <25% [<10% for Total 14 C] Time (hours) after start of 15-minute infusion
27 Comparison of Intravenous v. Oral Provided confidence for progression of molecule.. Comparison of plasma concentrations of Drug X following IV (100µg) and Oral doses (250mg); IV data normalised to equivalent dose Concentration of Drug X in Plasma (ng/ml) Time (hours) Oral (dose of 250mg) IV data from 14C tracer of 100ug (Normalised to 250mg) F =~25%
28 Metabolite profile data Reconstructed radiochromatogram (HPLC followed by AMS) of pooled human urine (n=8), 0-24h after oral dose M16 M dpm/200ul HPLC Fraction M13 M11, M8 M15 Parent drug 0.10 M6, M Time (min.) Note : profile reflects excreted radioactive drug-related components from IV dose NB: Peak assignments are based upon co-chromatography to spiked standards of Parent drug + 2 authentic metabolites, in the HPLC separation during isolation of fractions for analysis by AMS, and/or on assessments by MS and NMR
29 IV Tracer + Therapeutic Oral - Metabolism Data from metabolic profiling informs for further development strategies provide useful data for safety assessment and clinical study designs assessment of total observed drug related material in urine (NMR) metabolite profiling of urine & plasma pool; by AMS, MS & NMR each technology provides different insights eg. 14 C use allows assessment of extraction recoveries enables comparison of 14 C profile in animals and human to assess MIST issues IV/PO comparison - assessment of first pass metabolism influence Future studies - Addition of bile sampling provides another insight to elimination pathways
30 Summary Many recent changes all of which are contributing to a greater flexibility in study design easier application of innovative designs decision making studies at CS and later stages of development IV µtracer design may be the most important/influential of the new designs (?) Go/ No Go decisions on molecules in Phase 1 based on F% Design allows further assessments for metabolism investigations (including bile collection) GSK establishing an early clinical trials advisory board to help educate and facilitate for microdosing and tracer studies It seems like a wavefront..rather than just a ripple
31 ACKNOWLEDGEMENTS Many GSK colleagues; particularly Steve Corless and Clive Felgate Xceleron Ltd., particularly for their assistance in the early AMS studies Xceleron (AMS CRO) and Covance for support of the DDI study VITALEA (AMS CRO), SIMBEC and Quotient (fpharmaceutical Profiles) for support of the IV tracer study PRA for support of the IV PK Phase 0 study
32 Back-ups
33 Regulations.. Advent of biomedical AMS (Accelerator Mass Spec.) lead to. microdosing for PK/metabolism EMEA Position paper (2004) 1 ; principle of 1/100th of proposed pharmacological dose - never to exceed 100µg US FDA Exploratory IND (Jan 2006) 2 ; same definition, slightly different (reduced) toxicology package required FDA Critical path initiative 3 encourages alternative approaches to Drug Discovery and Development, to promote innovation ICH M3 R2 guidance (June 2009); section 7.1 clearly outlines support for such approaches 1. EMEA position paper on non-clinical safety studies to support clinical trials with a single microdose: 2. FDA Guidance for industry Investigators and Reviewers. Exploratory IND Studies FDA critical path initiative:
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationHuman ADME Study Design Considerations in Healthy Subjects and in Patients
Human ADME Study Design Considerations in Healthy Subjects and in Patients Daria Stypinski BSc (Pharm), PhD Clinical Pharmacology Sciences Nov 18, 2015 Learning Goals and Outline What is a human ADME study?
More information3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant
Phase 0 Microdosing Studies with Renin Inhibitors J. Chris Jensen Consultant Speedel Holding Ltd. Basel, Switzerland Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationA novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationAMS: A smarter way to cut through the MIST. Bob Ings RMI-Pharmacokinetics
AMS: A smarter way to cut through the MIST Bob Ings RMI-Pharmacokinetics www.rmi-pharmacokinetics.com Objectives Brief overview of Accelerator Mass Spectrometry (AMS) and its history Reminder of the MIST
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationPractical Application of PBPK in Neonates and Infants, Including Case Studies
Practical Application of PBPK in Neonates and Infants, Including Case Studies Presented at the conference : Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A
More informationPreclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer
Preclinical Requirements for Therapeutic Studies in Humans with Advanced Cancer Scott Laurie MD, FRCPC The Ottawa Hospital Cancer Centre Associate Professor, University of Ottawa Disclosures I have no
More informationJ Clin Pharm OnlineFirst, published on September 23, 2009 as doi: /
J Clin Pharm OnlineFirst, published on September 23, 2009 as doi:.1177/0091270009343698 Microdose Pharmacokinetics of and, Candidate HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors, Following Oral
More informationEuropean public MRL assessment report (EPMAR)
15 November 2016 EMA/CVMP/351687/2016 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) (bovine species) On 17 October 2016 the European Commission adopted
More informationPhase I in clinical drug development
Phase I in clinical drug development M2 Pharmacocinétique 31 janvier 2013 Philippe Grosjean Sanofi R&D Clinical Sciences and Operations 1 New drug investigations in human Objectives of the clinical investigations
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency October 2008 EMEA/CHMP/ICH/383/1995 ICH Topic S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON DOSE SELECTION FOR CARCINOGENICITY
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationCurrent Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
More informationModeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients
Modeling & Simulation to support evaluation of Safety and Efficacy of Drugs in Older Patients Eva Bredberg, Director Global Clinical Pharmacology, AstraZeneca On behalf of EFPIA EMA Geriatrics Workshop
More informationAssay Cross Validation
Assay Cross Validation Recent experiences in transferring bioanalytical assays from sponsor to CRO partners and between CROs Stephen White EBF Open Symposium Barcelona 20 th Nov 2013 Assay Cross Validation
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationBuilding innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches
Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro
More informationAN2728 Clinical Data in Atopic Dermatitis
AN2728 Clinical Data in Atopic Dermatitis Karl Beutner, MD, PhD 1 Overview of AN2728 in Atopic Dermatitis Target Product Profile Safe and effective topical therapy for atopic dermatitis Efficacy in the
More informationConflict of Interest Statement
Specific Aspects and Approaches for Regulatory Evaluation of Pharmaceuticals in Two-Year Rodent Carcinogenicity Studies James A. Popp Stratoxon LLC Morgantown, PA Tel: 610.286.7592 popp@stratoxon.com Conflict
More informationDefinitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team
Definitive QTc Assessment in Early Phase Trials: Expectations from FDA s Interdisciplinary Review Team Jiang Liu, Ph.D. Scientific Lead for QT-IRT Division of Pharmacometrics Office of Clinical Pharmacology
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationRenal Impairment From Dettli to Guideline: What can we learn?
Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics
More information1 Introduction: The Why and How of Drug Bioavailability Research
j1 1 Introduction: The Why and How of Drug Bioavailability Research Han van de Waterbeemd and Bernard Testa Abbreviations ADME EMEA FDA NCE PD P-gp PK R&D Absorption, distribution, metabolism, and excretion
More informationUsing Pharmacokinetics (PK) as a Tool During the Evaluation of Target Animal Safety (TAS)
Using Pharmacokinetics (PK) as a Tool During the Evaluation of Target Animal Safety (TAS) Marilyn N. Martinez, Ph.D. Senior Research Scientist CVM-FDA Traditional paradigm for the target animal safety
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationAppropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach
Appropriate Use of Recovery Groups in Nonclinical Toxicity Studies: Value in a Science-Driven Case-by-Case Approach Veterinary Pathology 49(2) 357-361 ª The Author(s) 2012 Reprints and permission: sagepub.com/journalspermissions.nav
More informationDOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)
DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *) Guideline Title Dose Selection for Carcinogenicity Studies of Pharmaceuticals *) Legislative basis Directive 75/318/EEC as amended Date
More informationFDA Expectations and Evaluation of Inhalation Toxicology Studies
FDA Expectations and Evaluation of Inhalation Toxicology Studies Presented by Timothy McGovern, Ph.D. SciLucent, LLC Herndon, Virginia Development of inhalation products has unique regulatory aspects My
More informationIOM Workshop on Comparative Oncology Pharmacokinetics in Companion Animal Cancer Studies
IOM Workshop on Comparative Oncology Pharmacokinetics in Companion Animal Cancer Studies Daniel L. Gustafson, Ph.D. Professor Shipley University Chair in Comparative Oncology Director of Basic Research,
More informationPRA International Early Development Services Bioanalytical Laboratory
PRA International Early Development Services Bioanalytical Laboratory Bioanalytical Laboratories: Retain profitability in a competitive market A View from a Major CRO Houten October 8, 2009 Peter Ketelaar
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationO O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions
Simplifying Qual/Quan Analysis in Discovery DMPK using UPLC and Xevo TQ MS Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION The determination of the drug metabolism
More informationEXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS
EXPOSURE RESPONSE ANALYSIS TO EVALUATE A DRUG'S EFFECT ON ECG PARAMETERS Christine Garnett, PharmD DCRP, FDA April 6, 2016 CSRC/FDA Workshop: The Proarrhythmic Assessment of New Chemical Entities Disclosures
More informationBiomath M263 Clinical Pharmacology
Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2013 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/3/2013 Pharmacokinetics and Pharmacodynamics
More informationBioavailability trial design for products delivered via the inhalation route
Bioavailability trial design for products delivered via the inhalation route Jianmeng Chen, Suresh Doddapaneni, Ping Ji, Chandrahas G Sahajwalla Division of Clinical Pharmacology 2 US FDA/CDER/OTS/OCP
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationThe Comet Assay Tails of the (Un)expected
The Comet Assay Tails of the (Un)expected Use of the in vivo comet assay in pharmaceutical development Bas-jan van der Leede Janssen R&D Johnson & Johnson Pharmaceutical Companies Discovery Sciences Genetic
More informationAdaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient
Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics
More informationA unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure
A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,
More informationCombination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects
Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects MC. Rouan, J. Snoeys, S. Ouwerkerk-Mahadevan, R. Verloes,
More informationAGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA)
HESI ILSI Health and Environmental Sciences Institute AGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA) ADME Task Force Hugh A. Barton, PhD National Center for Computational Toxicology Office of Research
More informationMODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL
MODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL ABSTRACT Quantitative prediction of the magnitude of drug-drug interactions (DDI) is critical to underwriting patient
More informationSMe. Me NITROIMIDAZOLES FOR VISCERAL LEISHMANIASIS FEXINIDAZOLE AND VL-2098 SHYAM SUNDAR
SMe O 2 CH 2 O Me ITROIMIDAZOLES FOR VISCERAL LEISHMAIASIS FEXIIDAZOLE AD VL-2098 SHYAM SUDAR Target Product Profile for a CE Optimal Target Profile Target Label VL and PKDL VL Spp All species L. donavani
More informationIntroduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017
Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017 1 Outline Definition & Relevance of Pharmacokinetics
More informationREVISITING THE PHARMACOKINETICS IN PATIENTS
REVISITING THE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED RENAL FUNCTION IN THE LIGHT OF THE LATEST FDA AND EMA GUIDELINES 3 RD CONFERENCE OF EUROPEAN PHARMACOLOGICAL SOCIETIES EUROPEAN COMPETITIVENESS
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationRisk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response
Risk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response 2003 FDA/Industry Statistics Workshop Peter I. Lee, PhD Associate Director, Pharmacometrics OCPB, CDER, FDA Disclaimers
More informationPK/PD analysis in assessment of abuse deterrence
PK/PD analysis in assessment of abuse deterrence Megan J. Shram, PhD Director and Principal, Altreos Research Partners Inc. Adjunct Professor and Lecturer, Department of Pharmacology, University of Toronto
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R1) U.S. Department
More informationThe Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05
The Opportunity: Superior treatment of narcolepsy and cataplexy SKL-N05 1 TABLE OF CONTENTS Highlights Clinical Trials Narcolepsy Profile Ancillary Pharmacology Mechanism of Action Preclinical Pharmacology
More informationSafety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America
Safety Pharmacology Society Webinar: Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America Agenda Introduction GI presentation rescheduled Upcoming SPS
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University
More informationCase Study 2 Answers Spring 2006
Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThe regulatory landscape Stephen White on behalf of the EBF
The regulatory landscape Stephen White on behalf of the EBF http://www.europeanbioanalysisforum.eu Overview 1. MIST and DDI Guideline 2. Regulatory landscape for BA 3. Tiered Approach on BA of metabolites
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationTCP Transl Clin Pharmacol
TCP 2015;23(1):26-30 http://dx.doi.org/10.12793/tcp.2015.23.1.26 Bioequivalence study of Donepezil hydrochloride in healthy Korean volunteers ORIGINAL ARTICLE Yewon Choi 1, Su-jin Rhee 1, In-Jin Jang 1,
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationQT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services
QT Assessment: The new paradigm, but now what? Joy Olbertz PharmD, PhD Senior Director, Cardiovascular Safety Services The Evolution of ICH E14 Points to Consider Joint Health Canada/FDA Concept Paper
More informationPharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen
Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen Polina German, Maggie Wang, David Warren and Brian Kearney Gilead Sciences Foster City, CA,
More informationPharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples
Pharmacokinetics and bioavailability derived from various body fluids Saliva samples instead of plasma samples Willi Cawello, Schwarz BioSciences, Monheim am Rhein 1 Overview Introduction Sampling tissues/fluids
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationDr. Erin E. Chambers Waters Corporation. Presented by Dr. Diego Rodriguez Cabaleiro Waters Europe Waters Corporation 1
Development of an SPE-LC/MS/MS Assay for the Simultaneous Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid in Support of Alzheimer s Research Dr. Erin E. Chambers Waters Corporation Presented
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPublic Assessment Report Scientific discussion
Public Assessment Report Scientific discussion Cabergoline Sandoz (cabergoline) SE/H/899/01-03/DC This module reflects the scientific discussion for the approval of Cabergoline Sandoz. The procedure was
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationCiPA, Pre-clinical Testing. Derek Leishman PhD DSP & ICH S7B
CiPA, Pre-clinical Testing Derek Leishman PhD DSP & ICH S7B Outline Introduction Scenarios Conclusion Expressing an opinion What is not covered? Analysis/critique of the components too little time to try
More informationFDA Use of Big Data in Modeling and Simulations
FDA Use of Big Data in Modeling and Simulations Jeffry Florian, Ph.D., Division of Pharmacometrics, CDER/OTS/OCP/DPM DISCLAIMER: The views expressed in this presentation are that of the author and do not
More informationPharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS MICHELLE A. RUDEK, PHARM.D., PH.D. ASSOCIATE PROFESSOR OF ONCOLOGY AND MEDICINE JOHNS HOPKINS UNIVERSITY Disclosures Spouse Employed Novavax
More informationOral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)
Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF) Michael A. Rogawski, M.D., Ph.D. Professor of Neurology and Pharmacology School of Medicine University of California, Davis
More informationThe effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates
The effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates Varun Garg, PhD On behalf of Drs. N Adda, K Alves, G Chandorkar, J-E Lee, X Luo, F Smith, R van Heeswijk, and Y Yang Author
More informationTake-Home Exam Distributed: October 19, 2012, at 2:30 p.m. Due: October 24, 2012, at 1:30 p.m.
20.201 Take-Home Exam Distributed: October 19, 2012, at 2:30 p.m. Due: October 24, 2012, at 1:30 p.m. Directions: This take-home exam is to be completed without help from any other individual except Drs.
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationUse of Bridging Justifications to Support the Safety of Excipients in Generic Drug Products
Use of Bridging Justifications to Support the Safety of Excipients in Generic Drug Products Sruthi King, Ph.D. Pharmacology/Toxicology Team Leader Division of Clinical Review, Office of Generic Drugs Center
More informationnumares at a glance company overview 2014 Discover, understand and use biological systems high level NMR analytics
numares at a glance company overview 2014 Discover, understand and use biological systems high level NMR analytics Three benefits of numares 1 Supporting patients to receive better cure based on effective
More informationComparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018
More informationDevelopment of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization
Development of Canagliflozin: Mechanistic Absorption Modeling During Late-Stage Formulation and Process Optimization Nico Holmstock Scientist, Janssen R&D M CERSI 2017, BALTIMORE (USA) Canagliflozin An
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationBioequivalence Requirements: USA and EU
Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,
More informationPrinciples of Toxicokinetics/Toxicodynanics
Biochemical and Molecular Toxicology ENVR 442; TOXC 442; BIOC 442 Principles of Toxicokinetics/Toxicodynanics Kim L.R. Brouwer, PharmD, PhD kbrouwer@unc.edu; 919-962-7030 Pharmacokinetics/ Toxicokinetics:
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationEDUCATIONAL COMMENTARY METHADONE
EDUCATIONAL COMMENTARY METHADONE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education
More information